EN
Edward Nash Canaccord Genuity Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
23
Avg Return
Past Year
Past Year
4.9%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
88%
Neutral
12%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Drug Manufacturers - Specialty & Generic
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Buy
Initiated
| $62 |
35%
upside
| 1 | +1.4% |
0
%
| 19 Feb ‘26 14 days ago |
|
|
|
Buy
Maintained
| $100 |
194%
upside
| 6 | -12% |
0
%
| 23 Jan ‘26 1 month ago |
|
|
|
Hold
Downgraded
| $14 | – | 2 | +48% |
0
%
| 8 Jan ‘26 1 month ago |
|
|
|
Buy
Initiated
| $25 |
877%
upside
| 1 | +15% |
0
%
| 18 Dec ‘25 2 months ago |
|
|
|
Buy
Maintained
| $587 |
34%
upside
| 4 | +9.1% |
0
%
| 13 Nov ‘25 3 months ago |
|
|
|
Buy
Maintained
| $107 |
240%
upside
| 2 | -3.1% |
0
%
| 12 Nov ‘25 3 months ago |
|
|
|
Hold
Downgraded
| $54 | – | 1 | -10% |
–
| 9 Oct ‘25 4 months ago |
|
|
|
Buy
Maintained
| $28 |
414%
upside
| 2 | -25% |
0
%
| 2 Oct ‘25 5 months ago |
|
|
|
Buy
Maintained
| $20 |
231%
upside
| 1 | +3.1% |
0
%
| 30 Sep ‘25 5 months ago |
|
|
|
Buy
Maintained
| $62 |
111%
upside
| 3 | +15% |
0
%
| 17 Sep ‘25 5 months ago |
|
|
|
Hold
Downgraded
| $107 | – | 1 | +46% |
–
| 9 Jul ‘25 7 months ago |
|
|
|
Buy
Maintained
| $47 |
72%
upside
| 1 | +90% |
0
%
| 10 Apr ‘25 10 months ago |
|